Passage Bio explores sale after FDA requires randomized trial for lead FTD program

Filed April 20, 2026 · Period ending April 20, 2026 · ~1 min read

Key Changes

• high

  FDA mandates randomized controlled trial for PBFT02 approval in FTD-GRN, creating what company calls 'ethical, logistical, and financial challenges.' Company now evaluating next steps for its lead asset.

  Item 8.01: FDA Feedback view on EDGAR →
• high

  Board initiated formal review of strategic alternatives including merger, acquisition, asset sale, or partnerships. Wedbush PacGrow engaged as financial advisor. Company acknowledges no transaction may occur.

  Item 8.01: Strategic Review view on EDGAR →
• medium

  Phase 1/2 trial showed PBFT02 reduced whole brain atrophy by 64% and frontotemporal cortex atrophy by 54% at 12 months in FTD-GRN patients versus natural history data. Plasma biomarkers stabilized through 18 months with no new safety concerns.

  Item 8.01: Clinical Data view on EDGAR →